Publication | Closed Access
Fusion of Dendritic Cells and Cancer-Associated Fibroblasts for Activation of Anti-Tumor Cytotoxic T Lymphocytes
45
Citations
0
References
2018
Year
ImmunologyImmune RegulationCancer-associated FibroblastsImmunoeditingImmunologic MechanismImmunotherapeuticsImmunotherapyTumor BiologyPolyethylene GlycolInflammationTumor ImmunityRadiation OncologyCell TransplantationTumor GrowthImmunoengineeringImmune SurveillanceT Cell ImmunityCell BiologyTumor MicroenvironmentDendritic CellsCancer ImmunosurveillanceImmune Checkpoint InhibitorImmunomodulationDendritic Cell BiologyCellular Immune ResponseMedicine
Here we explored the fusion of dendritic cells (DCs), potent antigen-presenting cells that initiate primary immune responses, with cancer-associated fibroblasts (CAFs), which are a stromal component needed for tumor progression, with the aim of stimulating T cells to inhibit tumor growth. Dendritic cells from the bone marrow of BALB/c mice were co-cultured with CAFs from H22 mouse hepatoma cells. CAFs were found to express fibroblast activation protein and α-smooth muscle actin by flow cytometry, Western blotting and immunofluorescence. Polyethylene glycol was added to the co-culture medium to encourage fusion, and the ability of the resulting fusion cells to produce TNF-α, IL-1β, IL-6, and IL-12p70 was confirmed using ELISA. These fusion cells efficiently stimulated T lymphocytes in vitro, causing them to generate IFN-α and IFN-γ. T cells activated by DC/CAF fusion cells led to strong CTL response against CAFs in vitro. The activated T cells also inhibited growth of H22 xenografts in vivo. These results indicate that DC/CAF fusion cells show potential for stimulating T cells as a novel anti-tumor vaccine.